The default is injection, and there is a reason
Almost every peptide compound on this site, from semaglutide in its original form to research peptides like BPC-157, was studied and developed as an injection. That is not a marketing choice. It follows from basic chemistry.
A peptide is a short chain of amino acids held together by peptide bonds. Those are exactly the bonds that digestive enzymes such as pepsin and trypsin exist to break, and stomach acid degrades many peptide structures on its own. A peptide that somehow survived that gauntlet intact then faces a second barrier: the gut wall, built to let through small molecules like sugars and salts while keeping most larger, water-attracting molecules out. Even a peptide that gets past both barriers still passes through the liver before reaching general circulation, which can strip away more of the dose before it does anything. Injection routes around the entire problem by placing the peptide directly into tissue or blood.
This is why, historically, turning a working injectable peptide into a viable pill has been one of the harder problems in drug development, and why the two approved examples below are worth looking at closely.
Oral semaglutide: a peptide with an escort molecule
Semaglutide is sold as a weekly subcutaneous injection (Ozempic, Wegovy) and, separately, as a once-daily tablet (Rybelsus). The tablet works by pairing the peptide with SNAC (salcaprozate sodium), an absorption enhancer. According to the FDA label, SNAC facilitates the absorption of semaglutide after oral administration, allowing a fraction of the dose to cross the stomach lining before enzymes degrade it.
The word "fraction" is doing real work there. The Rybelsus label states that population pharmacokinetic modelling puts absolute oral bioavailability at approximately 0.4% to 1%, meaning the vast majority of a swallowed dose never reaches the bloodstream at all. That is why the tablet needs a much higher labelled milligram dose than the injectable version to reach a useful blood level.
The dosing rules that come with it follow directly from that low and fragile absorption: the label instructs patients to take it at least 30 minutes before the first food, beverage or other oral medicine of the day, with no more than 4 ounces of plain water. Taking it with food, or with more liquid, measurably reduces how much gets absorbed. This is the clearest real-world illustration of why oral peptides are hard: even a formulation specifically engineered and FDA-approved for oral use absorbs at under 1%.
Orforglipron: the workaround is not being a peptide at all
Orforglipron, approved by the FDA in 2026 as Foundayo, takes a different route entirely. It is not a peptide. It is a small synthetic molecule that happens to activate the same GLP-1 receptor semaglutide does, which means it does not have peptide bonds for digestive enzymes to target and does not need an absorption enhancer to survive the stomach. The label allows it to be taken with or without food, at any time of day, a meaningfully simpler regimen than oral semaglutide's fasting rule.
The trade-off shows up in effect size rather than convenience: in its pivotal trial, mean weight loss among people who stayed on the highest orforglipron dose was smaller than what injectable semaglutide and tirzepatide reported in their own separate trials. Orforglipron's appeal is that it is genuinely a normal pill; it is not a demonstration that oral dosing closes the effectiveness gap with injection.
What "oral BPC-157" claims are actually based on
BPC-157 is often marketed with claims that it works taken by mouth, sometimes citing that it was originally identified in, and is described as stable in, human gastric juice. That description appears across the published animal literature and is the real basis for the oral-stability argument: unlike most peptides, it was not immediately destroyed by the stomach environment in laboratory testing.
What that does not establish is oral effectiveness in people. The rodent studies behind BPC-157's evidence base do include work where the peptide was given through drinking water or directly into the stomach, alongside separate studies using injection, and researchers have reported gut-protective and healing effects using those oral routes in that species. No human trial, however, has tested an oral BPC-157 product for any outcome, and gastric stability in a rat study is not the same claim as reliable absorption into human blood at a dose that does anything. The honest summary is that an oral-route rationale exists in the animal literature, and it has not been tested in a person.
Reading a supplier's oral claim
The two approved examples above give a useful checklist for evaluating any other "now available as capsules" claim in this space. Does the product name an absorption enhancer, the way Rybelsus names SNAC, or does it simply assert the peptide "survives digestion"? Is there a published bioavailability figure, even a low one, or none at all? Has the oral version been tested in a trial separate from the injectable form, the way ATTAIN and ACHIEVE tested orforglipron on its own terms? A capsule label alone answers none of these questions, and neither semaglutide's nor orforglipron's approval came without that underlying trial and pharmacokinetic work.
The practical distinction
Route matters because it decides how much of a labelled or claimed dose reaches the body doing anything at all. Injection remains the default for peptides because it sidesteps digestion entirely. Oral semaglutide shows that a peptide can be made to work by mouth, at the cost of single-digit-percent absorption and a strict dosing ritual. Orforglipron shows that the cleaner oral solution, so far, has been to stop using a peptide and use a small molecule instead. Claims about an oral peptide that skip past both of those examples, without an absorption enhancer, a bioavailability figure, or a human trial behind them, are asking to be taken on faith rather than evidence.
